Table 3.
The Relationships of ex-vivo Drug Resistance Assay with Clinicopathological Features and the Clinical Responses to Chemotherapy among Ovarian/Fallopian Cancer Patients
| Ex-vivo drug resistance assay | |||||
|---|---|---|---|---|---|
| Clinicopathological parameters | EDR (n=6) | IDR (n=3) | LDR (n=10) | P value | |
| Age (y) (n=19) | < 60 (n=12) | 5 | 1 | 6 | 0.326 |
| ≥ 60 (n=7) | 1 | 2 | 4 | ||
| FIGO staging (n=19) | Early (n=8) | 1 | 0 | 7 | 0.031* |
| Late (n=11) | 5 | 3 | 3 | ||
| Histological types (n=19) | Serous (n=13) | 5 | 3 | 5 | 0.168 |
| Mucinous (n=2) | 1 | 0 | 1 | ||
| Endometroid(n=3) | 0 | 0 | 3 | ||
| Granulosa (n=1) | 0 | 0 | 1 | ||
| Clinical response to chemotherapy (n=10) | Responsive (n=7) | 4 | 0 | 3 | 0.27 |
| Non-responsive (n=3) | 1 | 1 | 1 | ||
EDR, extreme drug resistance; IDR, intermediate drug resistance; LDR, low drug resistance.